Camp4 Therapeutics Corp (CAMP) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

CAMP4 announced positive preclinical data for CMP-002 showing improved seizure threshold and severity in a SYNGAP1-related disorder model, demonstrating therapeutic potential in a rare genetic neurological disorder with limited treatment options.
The company is actively advancing its pipeline through data presentations and investor communications, updating corporate materials to highlight clinical progress which may support future funding or partnership discussions.
This is a Regulation FD disclosure of non-material information (preclinical data presentation), indicating the company is in early-to-mid stage development with no immediate revenue impact, typical for clinical-stage biotech companies.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-07

Camp4 Therapeutics released Q1 2026 financial results on May 7, 2026, indicating the company is actively communicating operational and financial performance to shareholders.
The filing is a routine earnings announcement with no indication of material events, acquisitions, leadership changes, or significant agreements that would materially impact the company's strategic direction.
As an emerging growth company, Camp4 has elected standard compliance timelines for accounting standards, suggesting the company is utilizing available regulatory flexibility typical for earlier-stage public biotech firms.

Filed: 2026-03-24

Camp4 Therapeutics has appointed Michael MacLean, an experienced biotechnology finance executive, as a new director on the Board.
MacLean has over 35 years of financial leadership experience in the biotech and life sciences industry, with expertise in public company reporting, capital markets, internal controls, and corporate governance.
The company has updated its non-employee director compensation policy to grant 56,000 stock options to directors appointed after the effective date, including MacLean.

Filed: 2026-03-05

CAMP4 Therapeutics Corporation reported its 2025 financial results, indicating that the company continues to make progress in its drug development pipeline.
The company has updated its corporate presentation, providing investors with the latest information on its business and pipeline.
As an emerging growth company, CAMP4 Therapeutics has elected not to use the extended transition period for complying with new or revised financial accounting standards.

Filed: 2026-01-09

Camp4 Therapeutics Corporation, a Delaware-based biopharmaceutical company, has updated its corporate presentation, providing investors with a summary of its business activities.
The company's stock trades on the Nasdaq Global Market under the ticker symbol CAMP, indicating it is an emerging growth company that has elected not to use the extended transition period for complying with new or revised financial accounting standards.
The updated presentation is available on the company's investor relations website, suggesting the management team is actively engaging with the investment community to provide updates on the company's progress.

Other reports for Camp4 Therapeutics Corp

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.